Pregled bibliografske jedinice broj: 1110424
Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?
Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy? // European Journal of Preventive Cardiology, 28 (2021), zwab021, 3 doi:10.1093/eurjpc/zwab021 (međunarodna recenzija, kratko priopcenje, znanstveni)
CROSBI ID: 1110424 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Anticoagulation therapy in non-valvular atrial
fibrillation in the COVID-19 era: is it time to
reconsider our therapeutic strategy?
Autori
Papakonstantinou, Panteleimon E. ; Borovac, Josip Anđelo ; Gasecka, Aleksandra ; Bongiovanni, Dario ; Ehrlinder, Hanne ; Giustozzi, Michela ; Parker, William A.E. ; Azevedo Guerreiro, Rui
Izvornik
European Journal of Preventive Cardiology (2047-4873) 28
(2021);
Zwab021, 3
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, kratko priopcenje, znanstveni
Ključne riječi
atrial fibrillation ; anticoagulation ; NOAC ; DOAC ; novel oral anticoagulants ; interactions ; warfarin
Sažetak
This article deals about initiation of NOAC therapy in COVID- 19 outpatients with non-valvular atrial fibrillation vs. vitamin K antagonists.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
